A |
Absorption
|
Adherence
|
Adverse drug event
|
Adverse drug reaction
|
Affinity
|
Agonist
|
Allele
|
Allosteric modulator
|
Allosteric site
|
Antagonist
|
Apparent volume of distribution (Vd)
|
AUC
|
B
|
Bioavailability (F)
|
Biological marker (Biomarker)
|
Biotransformation
|
C |
Cheng-Prusoff equation
|
Clinical trials
|
Competitve antagonist
|
Competitive inhibitor
|
Concentration-time curve
|
Conformational change
|
Constitutive activity
|
D |
Desensitization
|
Dose-response relationships
|
Drug clearance
|
Drug concentration
|
Drug transport
|
E |
Efficacy
|
Enteral drug administration
|
Enzyme
|
Equilibrium dissociation constant (Kd)
|
F |
First-pass effect
|
Full agonist
|
G |
Graded dose-response curve
|
H |
Half-life
|
Haplotype
|
I |
IC50
|
Informed consent document
|
Inhibitory constant (Ki)
|
Inverse agonist
|
Irreversible antagonist
|
J |
K |
L |
Ligand
|
M |
Maximum Activation Potential Vmax
|
Metabolic drug tolerance
|
Metabolism
|
Metabolite
|
Michaelis constant (Km)
|
N |
Non-competitive antagonist
|
O |
Observational studies
|
Orthosteric site
|
P |
Parent compound
|
Parenteral drug administration
|
Partial agonist
|
Pharmacodynamics
|
Pharmacogenetics
|
Pharmacogenomics
|
Pharmacokinetics (PK)
|
Pharmacology
|
Phase I Clinical Trial
|
Phase II Clinical Trial
|
Phase III Clinical Trial
|
Phase IV Clinical Trial
|
Potency
|
Prodrug
|
Q |
Quantal dose-response curve
|
R |
Randomized controlled trials
|
Receptor
|
Receptor pharmacology
|
Reversible antagonist
|
S |
Side effect
|
Spare receptors
|
Substrate
|
T |
Tachyphylaxis
|
Therapeutic index
|
Therapeutics
|
Tolerance
|
Toxicology
|
Transporter
|
U |
V |
W |
Wild type
|
X |
Y |
Z |